WHO WE ARE

ICMRA is an informal group of leaders of medicines regulatory authorities that provides strategic directions for enhanced collaboration, improved communication and approaches to jointly address common challenges, such as the COVID-19 pandemic.

MISSION

ICMRA's mission is to safeguard public health by facilitating strategic leadership and greater cooperation of international medicines authorities on shared regulatory issues and challenges.

MAIN OBJECTIVES

ICMRA promotes international cooperation among medicines regulatory authorities to strengthen global dialogue, facilitate the wider exchange of reliable and comparable information, encourage greater leveraging of resources and work between authorities, and advocate for better informed risk-based allocation of authorities’ resources and deeper collaboration among them. The group also addresses current and emerging human medicine regulatory and safety challenges. These efforts aim to strengthen the quality, safety and efficacy of medicinal products globally.

MAIN WORKING AREAS

There are currently several ICMRA projects on Antimicrobial Resistance (AMR), Communications, Drug shortages, Innovation, Pharmacovigilance, Public health response, and Supply chain integrity.

HOW TO JOIN ICMRA

Interested authorities can contact the ICMRA Secretariat: ICMRAcoordination@ema.europa.eu

ICMRA website: http://www.icmra.info/drupal/en
MEMBERS

- Australia: Therapeutic Goods Administration (TGA)
- Brazil: National Health Surveillance Agency (ANVISA)
- Canada: Health Products and Food Branch Health Canada (HPFB-HC)
- China: National Medical Products Administration (NMPA)
- European Union: European Commission Directorate-General for Health and Food Safety (DG SANTE)
- European Union: European Medicines Agency (EMA)
- France: National Agency for the Safety of Medicines and Health Products (ANSM)
- Germany: Paul-Ehrlich-Institut (PEI)
- Mexico: Federal Commission for Protection against Health Risks (COFEPRIS)
- India: Ministry of Health and Family Welfare (MoHFW)
- Ireland: Health Products Regulatory Authority (HPRA)
- Italy: Italian Medicines Agency (AIFA)
- Japan: Ministry of Health, Labour and Welfare (MHLW)
- Japan: Pharmaceuticals and Medical Devices Agency (PMDA)
- Republic of Korea: Ministry of Food and Drug Safety (MFDS)
- The Netherlands: Medicines Evaluation Board (CBG-MEB)
- New Zealand: New Zealand Medicines and Medical Devices Safety Authority (Medsafe)
- Nigeria: National Agency for Food and Drug Administration and Control (NAFDAC)
- Singapore: Health Sciences Authority, Singapore (HSA)
- South Africa: South African Health Products Regulatory Authority (SAHPRA)
- Sweden: Swedish Medicines Products Agency (MPA)
- Switzerland: Swissmedic
- UK: Medicines & Healthcare products Regulatory Agency (MHRA)
- US: Food and Drug Administration (FDA)

ASSOCIATE MEMBERS

- Argentina: National Administration of Drugs, Foods and Medical Devices (ANMAT)
- Austria: Austrian Medicines and Medical Devices Agency (AGES)
- Colombia: National Food and Drug Surveillance Institute (INVIMA)
- Cuba: Center for State Control of Medicines, Equipment and Medical Devices (CECMED)
- Denmark: Danish Medicines Agency (DKMA)
- Israel: Ministry of Health (MOH)
- Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)
- Portugal: National Authority of Medicines and Health Products (INFARMED)
- Russia: Federal Service for Surveillance in Healthcare (Roszdravnadzor)
- Saudi Arabia: Saudi Food & Drug Authority (SFDA)
- Spain: Spanish Agency of Medicines and Medical Devices (AEMPS)

OBSERVERS

- World Health Organization (WHO)

Last updated: June 2021